Clinical Trials Logo

Clinical Trial Summary

This study aims to investigate the efficacy and safety of depemokimab compared with mepolizumab in adults with relapsing or refractory EGPA receiving SoC therapy.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT05263934
Study type Interventional
Source GlaxoSmithKline
Contact US GSK Clinical Trials Call Center
Phone 877-379-3718
Email GSKClinicalSupportHD@gsk.com
Status Recruiting
Phase Phase 3
Start date July 14, 2022
Completion date November 7, 2025

See also
  Status Clinical Trial Phase
Recruiting NCT02967068 - VCRC Tissue Repository
Recruiting NCT05979051 - A Study to Evaluate the Efficacy and Safety of SHR-1703 in Subjects With Eosinophilic Granulomatosis With Polyangiitis (EGPA) Phase 2/Phase 3
Recruiting NCT05030155 - Study of Mepolizumab-based Regimen Compared to Conventional Therapeutic Strategy in Patients With Eosinophilic Granulomatosis With Polyangiitis (E-merge) Phase 3
Active, not recruiting NCT03164473 - Maintenance of Remission With Rituximab Versus Azathioprine for Newly-diagnosed or Relapsing Eosinophilic Granulomatosis With Polyangiitis. Phase 3
Recruiting NCT02006134 - Pediatric Vasculitis Initiative
Recruiting NCT06046222 - Trial of Efficacy and Safety of NS-229 Versus Placebo in Patients With Eosinophilic Granulomatosis With Polyangiitis Phase 2
Completed NCT04280601 - PRagmatic Analysis of Vitamin D in ANCA-Associated Vasculitis N/A
Not yet recruiting NCT06231498 - The Epigenomic Signature of Eosinophilic Granulomatosis With Polyangiitis
Recruiting NCT00315380 - Longitudinal Study for Eosinophilic Granulomatosis With Polyangiitis (Churg-Strauss)
Completed NCT03298061 - Long-term Access Program (LAP) of Mepolizumab for Subjects Who Participated in Study MEA115921 Phase 3